Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma

Basit Öğe Kaydı
dc.contributor.authorSurmeli, Zeki G.
dc.contributor.authorOzveren, Ahmet
dc.contributor.authorArslan, Cagatay
dc.contributor.authorDegirmenci, Mustafa
dc.contributor.authorKaraca, Burcak
dc.contributor.authorUslu, Ruchan
dc.date.accessioned2019-10-27T09:48:28Z
dc.date.available2019-10-27T09:48:28Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractBACKGROUND AND AIM: The combination of cetuximab with platinum and 5-fluorouracil (5-FU) chemotherapy prolongs survival in patients with metastatic or recurrent squamous-cell carcinoma of the head and neck (SCCHN). Biweekly (once in 2 weeks) administration of cetuximab requires fewer hospital visits and decreases treatment costs; therefore, it is more convenient both for the patients and for the healthcare providers. Here, we assessed the efficacy, safety, and tolerability of an alternative biweekly regimen of cetuximab in combination with platinum and 5-FU chemotherapy as a first-line treatment for these patients. METHODS AND MATERIALS: Medical records of patients with metastatic or recurrent non-nasopharyngeal SCCHN who were treated with a biweekly regimen of cetuximab (500 mg/m(2) on day 1), cisplatin (40 mg/m(2) on day 1) or carboplatin (target area under the curve 3.5 mg/ml x min on day 1), folinic acid (400 mg/m(2) on day 1), and 5-FU (400 mg/m(2) bolus on day 1 followed by continuous infusion of 2,400 mg/m(2) 5-FU over 46 h) were retrospectively reviewed. Survival estimates were calculated with the Kaplan-Meier method. RESULTS: In total, 60 patients were included. The median age of the patients was 60.5. The objective response rate was 53.3% (95% confidence interval [CI] = 40.7-65.9). The median progression-free survival duration was 6.8 months (95% CI = 5.5-8.1) and the median overall survival duration was 13.3 months (95% CI = 8.4-18.2). The most common grade 3 or 4 adverse events were neutropenia (28.3%) and leucopenia (13.3%). Grade 3 or 4 rash was observed in 3.3% of the patients. CONCLUSION: Biweekly administration of cetuximab, cisplatin, and 5-FU is an effective regimen with a favorable toxicity profile for the first-line treatment of metastatic or recurrent SCCHN. These results warrant further evaluation of this regimen in prospective trials.en_US
dc.identifier.doi10.4103/ijc.IJC_355_18
dc.identifier.endpage8en_US
dc.identifier.issn0019-509X
dc.identifier.issn1998-4774
dc.identifier.issn0019-509Xen_US
dc.identifier.issn1998-4774en_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage4en_US
dc.identifier.urihttps://doi.org/10.4103/ijc.IJC_355_18
dc.identifier.urihttps://hdl.handle.net/11454/29529
dc.identifier.volume56en_US
dc.identifier.wosWOS:000463520600002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofIndian Journal of Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCetuximaben_US
dc.subjectchemotherapyen_US
dc.subjecthead and neck canceren_US
dc.subjectlarynx canceren_US
dc.subjecttargeted therapyen_US
dc.titleBiweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu